Here in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent ...

A lawsuit filed by a national pharmacy chain and its subsidiaries in the Little Rock federal court on Thursday seeks to ...

A lawsuit was filed in Little Rock federal court on Thursday to overturn an Arkansas law preventing pharmacy benefit managers ...

Choosing dividend stocks is not only about looking at the yield but also ensuring that the company pays regular dividends, ...

The hedge fund billionaire’s take on how to fix America’s fiscal woes is getting a warm reception in Washington, even as he ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

A patient in a Rocket Pharmaceuticals gene therapy trial for a rare heart condition has died, the company said.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

According to President Trump, CMS Administrator Mehmet Oz is a “tough hombre” who can bring down drug costs “like a rock.” ...

They worry tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business ...